BioSpace News Archive

Foghorn ® Therapeutics Inc. today announced that the Company will present new data at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit.

Societal CDMO, Inc. today announced that it has signed CDMO service agreements with two new customers.

Axogen, Inc. today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022 before the market opens.

SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher long-term returns are expected, given the promising data generated to date in refractory fungal infections, including Candida auris, and the anticipated first approval in the hospital setting in 2024.

atai Life Sciences N.V. today announced the agenda for its virtual R&D Day.

Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that it will report third quarter fiscal 2022 financial results on Thursday, November 10, 2022, before the market opens. In conjunction, the company will host a conference call to review results at 8:00 a.m.

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2022 after the market closes on Thursday, October 27, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Shields Health Solutions (Shields), the nation’s premier specialty pharmacy accelerator, is proud to award a resident research grant in the amount of $5,000 to supplement existing projects or initiatives which advance health system specialty pharmacy in Q4 of 2022.

Kala Pharmaceuticals, Inc. today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.

Kymera Therapeutics, Inc. will report third quarter 2022 financial results on November 3, 2022 and will host a conference call at 8:30 a.m. ET that day.